About this document "Sample Pathology Report - Breast Cancer": What are the key findings in this pathology report

Key Findings in Your Pathology Report

Based on this specific pathology report for Jane Doe, here are the most important findings:

Cancer Type and Characteristics

Invasive Ductal Carcinoma (IDC) - This is the most common type of breast cancer, where cancer cells have grown beyond the milk ducts into surrounding breast tissue. According to NCCN Guidelines, invasive breast cancer means the cancer "has grown outside the ducts or lobules into surrounding tissue."

• Tumor Size: 1.8 cm (about 0.7 inches)
• Grade 2: Moderately differentiated, meaning the cancer cells look somewhat abnormal but not extremely aggressive
• Clean Margins: The surgical margins are negative (0.3 cm clear), meaning no cancer cells were found at the edges of the removed tissue

Hormone Receptor Status (Critical for Treatment Planning)

Your report shows hormone receptor-positive, HER2-negative breast cancer:

• ER Positive: 95% of tumor cells (strong) - the cancer responds to estrogen
• PR Positive: 80% of tumor cells (moderate to strong) - the cancer responds to progesterone
• HER2 Negative: Score of 0 - the cancer doesn't have excess HER2 protein

According to NCCN Guidelines for Patients: Invasive Breast Cancer, these biomarker tests "provide information about the behavior of your cancer, as well as treatments to which your cancer may respond." Your hormone-positive status means endocrine (hormone) therapy will likely be an important part of your treatment.

Lymph Node Status

Node Negative (pN0) - Both sentinel lymph nodes examined showed no cancer spread. This is very favorable news, as the NCCN Guidelines note that cancer spreading to lymph nodes affects staging and treatment decisions.

Stage

pT1c N0 - Stage IIA - This staging is based on:

• T1c: Tumor between 1-2 cm
• N0: No lymph node involvement
• The "p" indicates this is pathologic staging (determined after surgery)

Treatment Implications

The pathologist specifically recommends:

1. Endocrine (hormone) therapy - because of your strong hormone receptor positivity
2. Oncotype DX testing consideration - a genomic test that can help determine whether chemotherapy would provide additional benefit beyond hormone therapy

According to the American Cancer Society and NCCN Guidelines, Oncotype DX is particularly useful for hormone receptor-positive, HER2-negative, node-negative breast cancers like yours to personalize treatment decisions.

What This Means

This report shows early-stage, hormone-responsive breast cancer with no lymph node spread - features generally associated with favorable outcomes when treated appropriately. Your oncologist will use these specific findings to create a personalized treatment plan.

Important: Please discuss these findings thoroughly with your oncology team, who can explain how they apply specifically to your situation and treatment options.